Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2718-2728

  Grabiec, Aleksander M ^a   Krausz, Sarah ^a   De Jager, Wilco ^b   Burakowski, Tomasz ^c   Groot, Dion ^a   Sanders, Marjolein E ^a   Prakken, Berent J ^b   Maslinski, Wlodzimierz ^c   Eldering, Eric ^a   Tak, Paul P ^a   Reedquist, Kris A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; NICOTINAMIDE; SIRTUIN 3; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; BCL2-RELATED PROTEIN A1; HYDROXAMIC ACID; PROTEIN BCL 2; SUBEROYL BIS HYDROXAMIC ACID; SUBEROYL BIS-HYDROXAMIC ACID;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM; CELL CULTURE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INFLAMMATION; INTERLEUKIN-6; MACROPHAGES; MALE; MIDDLE AGED; NIACINAMIDE; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951925741     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901467     Document Type: Article

References (62)

1. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429-442.
2. Kinne, R. W., B. Stuhlmüller, and G. R. Burmester. 2007. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res. Ther. 9: 224.
3. Huang, Q. Q., Y. Y. Ma, A. Adebayo, and R. M. Pope. 2007. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum. 56: 2192-2201.
4. Roelofs, M. F., S. Abdollahi-Roodsaz, L. A. Joosten, W. B. van den Berg, and T. R. Radstake. 2008. The orchestra of Toll-like receptors and their potential role in frequently occurring rheumatic conditions. Arthritis Rheum. 58: 338-348.
5. Drexler, S. K., P. L. Kong, J. Wales, and B. M. Foxwell. 2008. Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis. Arthritis Res. Ther. 10: 216.
6. Mulherin, D., O. Fitzgerald, and B. Bresnihan. 1996. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 39: 115-124. (Pubitemid 26036386)
7. Tak, P. P., T. J. Smeets, M. R. Daha, P. M. Kluin, K. A. Meijers, R. Brand, A. E. Meinders, and F. C. Breedveld. 1997. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 40: 217-225.
8. Liu, H., and R. M. Pope. 2003. The role of apoptosis in rheumatoid arthritis. Curr. Opin. Pharmacol. 3: 317-322.
9. Haringman, J. J., M. C. Kraan, T. J. Smeets, K. H. Zwinderman, and P. P. Tak. 2003. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62: 715-721.
10. Haringman, J. J., D. M. Gerlag, A. H. Zwinderman, T. J. Smeets, M. C. Kraan, D. Baeten, I. B. McInnes, B. Bresnihan, and P. P. Tak. 2005. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64: 834-838.
11. Urnov, F. D., and A. P. Wolffe. 2001. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 20: 2991-3006.
12. Blanchard, F., and C. Chipoy. 2005. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov. Today 10: 197-204. (Pubitemid 40222231)
13. Minucci, S., and P. G. Pelicci. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6: 38-51.
14. Glozak, M. A., N. Sengupta, X. Zhang, and E. Seto. 2005. Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23.
15. Tas, S.W., P. H. Remans, K. A. Reedquist, and P. P. Tak. 2005. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr. Pharm. Des. 11: 581-611.
16. Reedquist, K. A., J. Ludikhuize, and P. P. Tak. 2006. Phosphoinositide 3-kinase signalling and FoxO transcription factors in rheumatoid arthritis. Biochem. Soc. Trans. 34: 727-730.
17. Cosío, B. G., B. Mann, K. Ito, E. Jazrawi, P. J. Barnes, K. F. Chung, and I. M. Adcock. 2004. Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma. Am. J. Respir. Crit. Care Med. 170: 141-147.
18. Ito, K., G. Caramori, S. Lim, T. Oates, K. F. Chung, P. J. Barnes, and I. M. Adcock. 2002. Expression and activity of histone deacetylases in human asthmatic airways. Am. J. Respir. Crit. Care Med. 166: 392-396.
19. Ito, K., M. Ito, W. M. Elliott, B. Cosio, G. Caramori, O. M. Kon, A. Barczyk, S. Hayashi, I. M. Adcock, J. C. Hogg, and P. J. Barnes. 2005. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352: 1967-1976.
20. Rajendrasozhan, S., S. R. Yang, V. L. Kinnula, and I. Rahman. 2008. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177: 861-870.
21. Cosio, B. G., L. Tsaprouni, K. Ito, E. Jazrawi, I. M. Adcock, and P. J. Barnes. 2004. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 200: 689-695.
22. Ito, K., S. Yamamura, S. Essilfie-Quaye, B. Cosio, M. Ito, P. J. Barnes, and I. M. Adcock. 2006. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203: 7-13.
23. Huber, L. C., M. Brock, H. Hemmatazad, O. T. Giger, F. Moritz, M. Trenkmann, J. H. Distler, R. E. Gay, C. Kolling, H. Moch, et al. 2007. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum. 56: 1087-1093.
24. Choi, J. H., S. W. Oh, M. S. Kang, H. J. Kwon, G. T. Oh, and D. Y. Kim. 2005. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 35: 89-96.
25. Glauben, R., A. Batra, I. Fedke, M. Zeitz, H. A. Lehr, F. Leoni, P. Mascagni, G. Fantuzzi, C. A. Dinarello, and B. Siegmund. 2006. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176: 5015-5022.
26. Camelo, S., A. H. Iglesias, D. Hwang, B. Due, H. Ryu, K. Smith, S. G. Gray, J. Imitola, G. Duran, B. Assaf, et al. 2005. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164: 10-21.
27. Leng, C., M. Gries, J. Ziegler, A. Lokshin, P. Mascagni, S. Lentzsch, and M. Y. Mapara. 2006. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hematol. 34: 776-787.
28. Li, N. N., D. Zhao, M. Kirschbaum, C. Zhang, C. L. Lin, I. Todorov, F. Kandeel, S. Forman, and D. F. Zeng. 2008. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl. Acad. Sci. USA 105: 4796-4801.
29. Reddy, P., Y. Sun, T. Toubai, R. Duran-Struuck, S. G. Clouthier, E. Weisiger, Y. Maeda, I. Tawara, O. Krijanovski, E. Gatza, et al. 2008. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118: 2562-2573.
30. Leoni, F., A. Zaliani, G. Bertolini, G. Porro, P. Pagani, P. Pozzi, G. Donà, G. Fossati, S. Sozzani, T. Azam, et al. 2002. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 99: 2995-3000.
31. Leoni, F., G. Fossati, E. C. Lewis, J. K. Lee, G. Porro, P. Pagani, D. Modena, M. L. Moras, P. Pozzi, L. L. Reznikov, et al. 2005. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11: 1-15.
32. Chung, Y. L., M. Y. Lee, A. J. Wang, and L. F. Yao. 2003. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8: 707-717.
33. Nakamura, T., T. Kukita, T. Shobuike, K. Nagata, Z. Wu, K. Ogawa, T. Hotokebuchi, O. Kohashi, and A. Kukita. 2005. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production. J. Immunol. 175: 5809-5816. (Pubitemid 41508065)
34. Nishida, K., T. Komiyama, S. Miyazawa, Z. N. Shen, T. Furumatsu, H. Doi, A. Yoshida, J. Yamana, M. Yamamura, Y. Ninomiya, et al. 2004. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50: 3365-3376.
35. Lin, H. S., C. Y. Hu, H. Y. Chan, Y. Y. Liew, H. P. Huang, L. Lepescheux, E. Bastianelli, R. Baron, G. Rawadi, and P. Clément-Lacroix. 2007. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150: 862-872.
36. Carta, S., S. Tassi, C. Semino, G. Fossati, P. Mascagni, C. A. Dinarello, and A. Rubartelli. 2006. Histone deacetylase inhibitors prevent exocytosis of interleukin-1b-containing secretory lysosomes: role of microtubules. Blood 108: 1618-1626. (Pubitemid 44316130)
37. Brogdon, J. L., Y. Xu, S. J. Szabo, S. An, F. Buxton, D. Cohen, and Q. Huang. 2007. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109: 1123-1130.
38. Grabiec, A. M., P. P. Tak, and K. A. Reedquist. 2008. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? Arthritis Res. Ther. 10: 226.
39. Choo, Q. Y., P. C. Ho, and H. S. Lin. 2008. Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Curr. Pharm. Des. 14: 803-820.
40. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
41. de Jager, W., B. J. Prakken, J. W. J. Bijlsma, W. Kuis, and G. T. Rijkers. 2005. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods 300: 124-135.
42. Eldering, E., C. A. Spek, H. L. Aberson, A. Grummels, I. A. Derks, A. F. de Vos, C. J. McElgunn, and J. P. Schouten. 2003. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res. 31: e153.
43. Kraan, M. C., R. J. Reece, T. J. Smeets, D. J. Veale, P. Emery, and P. P. Tak. 2002. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum. 46: 2034-2038.
44. Vaquero, A., M. Scher, D. Lee, H. Erdjument-Bromage, P. Tempst, and D. Reinberg. 2004. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 16: 93-105. (Pubitemid 39330155)
45. Haggarty, S. J.,K.M.Koeller, J.C.Wong, C.M.Grozinger, and S.L.Schreiber. 2003. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100: 4389-4394.
46. Huber, L. C., J. Stanczyk, A. Jüngel, and S. Gay. 2007. Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum. 56: 3523-3531.
47. Gregoretti, I. V., Y. M. Lee, and H. V. Goodson. 2004. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338: 17-31.
48. Bosisio, D., M. Vulcano, A. Del Prete, M. Sironi, V. Salvi, L. Salogni, E. Riboldi, F. Leoni, C. A. Dinarello, G. Girolomoni, and S. Sozzani. 2008. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 84: 1540-1548.
49. Raza, K., F. Falciani, S. J. Curnow, E. J. Ross, C. Y. Lee, A. N. Akbar, J. M. Lord, C. Gordon, C. D. Buckley, and M. Salmon. 2005. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 7: R784-R795.
50. Villagra, A., F. Cheng, H. W. Wang, I. Suarez, M. Glozak, M. Maurin, D. Nguyen, K. L. Wright, P. W. Atadja, K. Bhalla, et al. 2009. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 10: 92-100.
51. Sequeira, J., G. Boily, S. Bazinet, S. Saliba, X. He, K. Jardine, C. Kennedy, W. Staines, C. Rousseaux, R. Mueller, and M. W. McBurney. 2008. sirt1-null mice develop an autoimmune-like condition. Exp. Cell Res. 314: 3069-3074.
52. Carew, J. S., F. J. Giles, and S. T. Nawrocki. 2008. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269: 7-17.
53. Perlman, H., L. J. Pagliari, N. Nguyen, K. Bradley, H. Liu, and R. M. Pope. 2001. The Fas-FasL death receptor and PI3K pathways independently regulate monocyte homeostasis. Eur. J. Immunol. 31: 2421-2430.
54. Perlman, H., L. J. Pagliari, H. Liu, A. E. Koch, G. K. Haines, 3rd, and R. M. Pope. 2001. Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum. 44: 21-30. (Pubitemid 32113114)
55. Liu, H., Y. Ma, L. J. Pagliari, H. Perlman, C. Yu, A. Lin, and R. M. Pope. 2004. TNF-α-induced apoptosis of macrophages following inhibition of NF-kappa B: a central role for disruption of mitochondria. J. Immunol. 172: 1907-1915. (Pubitemid 38116841)
56. Perlman, H., L. J. Pagliari, C. Georganas, T. Mano, K. Walsh, and R. M. Pope. 1999. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J. Exp. Med. 190: 1679-1688.
57. Liu, H., H. Perlman, L. J. Pagliari, and R. M. Pope. 2001. Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation. J. Exp. Med. 194: 113-126.
58. Liu, H., Y. Ma, S. M. Cole, C. Zander, K. H. Chen, J. Karras, and R. M. Pope. 2003. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 102: 344-352. (Pubitemid 36759675)
59. Pagliari, L. J., H. Perlman, H. Liu, and R. M. Pope. 2000. Macrophages require constitutive NF-kappaB activation to maintain A1 expression and mitochondrial homeostasis. Mol. Cell. Biol. 20: 8855-8865.
60. Simmons, M. J., G. Fan, W. X. Zong, K. Degenhardt, E. White, and C. Gélinas. 2008. Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist. Oncogene 27: 1421-1428.
61. Khan, N., M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S. C. Berghs, N. Carey, et al. 2008. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409: 581-589.
62. Jüngel, A., V. Baresova, C. Ospelt, B. R. Simmen, B. A. Michel, R. E. Gay, S. Gay, C. A. Seemayer, and M. Neidhart. 2006. Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann. Rheum. Dis. 65: 910-912.